Welcoming our New Vice President of Development

The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation.

Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives.

Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.

“As an ambitious organization, we knew we needed a leader with a breadth of experience who can push us to the next level,” says Patti Pearce, The Max Foundation CFO and VP of Administration. “I have total confidence in Wilma’s leadership and experience to drive success.”

Wilma will join The Max Foundation’s Seattle headquarters office and oversee The Max Foundation’s development and communication departments.

“I am honored to have the opportunity to join The Max Foundation,” says Wilma. “I’ve been impressed with the organization from the start and feel connected to the mission of providing dignity and hope to cancer patients worldwide.”

Please join us in welcoming Wilma Comenat as The Max Foundation’s Vice President of Development.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation expands collaboration with Pfizer

    The Max Foundation expands collaboration with Pfizer

    The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.

  • The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

    The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

    In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low and middle income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.

  • The Max Foundation Delivers First Treatment into Mozambique

    The Max Foundation Delivers First Treatment into Mozambique

    On November 1, 2019, the first shipment of treatment arrived at the hospital in Maputo, Mozambique. This is the first country Max Access Solutions, The Max Foundation’s patient-centered access model, has expanded into without a former access program in place.